MedTrace Logo

Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients

NCT00160992 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2005-09-12

No results posted yet for this study

Summary

Patients with advanced stage melanoma who underwent vaccination with the Melan-A/MART-1 peptide and who display detectable levels of Melan-A specific CD8+ T cells in peripheral blood are eligible for this trial. After collecting and freezing of these tumor specific T cells via apheresis, patients undergo a single cycle of immunosuppressive chemotherapy. 3 days after, cells are reinfused and peptide vaccination continued. The aim of this immunotherapy protocol is to boost tumor specific T cells during the immune recovery period in order to reinforce the patients' immune response against the tumor.

Conditions

Interventions

BIOLOGICAL

Melan-A analog peptide

Sponsors & Collaborators

  • Fond'action contre le cancer

    collaborator UNKNOWN

  • Barletta Foundation

    collaborator OTHER

  • NCCR (National Center of Competence in Resaerch, Switzerland)

    collaborator NETWORK

  • University of Lausanne Hospitals

    lead OTHER

Principal Investigators

  • Verena Voelter, MD · Multidisciplinary Oncology Center, University of Lausanne Hospitals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Completion
2005-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160992 on ClinicalTrials.gov